Skip to main content

Animations

MJFF Publications

3801 - 3810 of 8824 Results
Title
Year
  • Year
  • 2025
  • 2024
  • 2022
  • 2025
  • 2025
  • 2025
  • 2025
  • 2025
  • 2023
  • 2025
  • Summary Details
    RESTRICTED
    Title: No anti-IgLON5 antibody in carefully diagnosed PSP patients with “atypical” or variant clinical features
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2025.108071
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Conquering Neurologic Diseases in Primary Care
    Journal Name: Primary Care: Clinics in Office Practice
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.pop.2024.03.001
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Anti-parkinsonian effect of the mGlu2 positive allosteric modulator LY-487,379 as monotherapy and adjunct to a low L-DOPA dose in the MPTP-lesioned marmoset
    Journal Name: European Journal of Pharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.ejphar.2022.175429
    Citation Count: 6
  • Summary Details
    OPEN
    Title: Effect of the mGlu2 receptor positive allosteric modulator AZD8529 on L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset
    Journal Name: European Journal of Pharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.ejphar.2025.178031
    Citation Count: 0
  • Summary Details
    OPEN
    Title: A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc, cc-by-nc
    DOI - Digital Object Identifier: 10.1177/1877718x251356503
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Midkine attenuates amyloid-β fibril assembly and plaque formation
    Journal Name: Nature Structural & Molecular Biology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41594-025-01657-8
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Chemical proteomics reveals human liver fatty acid binding protein as a predominant and selective target of triphenyl phosphate
    Journal Name: Environmental Science: Processes & Impacts
    Publisher: Royal Society of Chemistry (RSC)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1039/d5em00327j
    Citation Count: 1
  • Summary Details
    RESTRICTED
    Title: Dysphagia Is Associated with Incident Non‐Motor Symptoms in Parkinson's Disease
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mdc3.70297
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Long‐Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.29383
    Citation Count: 20
  • Summary Details
    OPEN
    Title: HT SpaceM: A high-throughput and reproducible method for small-molecule single-cell metabolomics
    Journal Name: Cell
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.cell.2025.08.015
    Citation Count: 12
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.